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Abstract: Currently, different statins are available for the treatment of dyslipidemia: Atorvastatin, Simvastatin, 
Rosuvastatin, Lovastatin, Pravastatin, and Fluvastatin; the newest entry in this class of drugs is Pitavastatin. 
The purpose of the present study was to examine the latest evidences on Pitavastatin, more than 10 years after its first 
marketing and focuses on the most recent evidence regarding its differences with other available statins. A literature 
review of the last 3 years (January 2013 - January 2016) has been carried out via Pub Med. 193 obtained items were 
analysed. 
Pitavastatin has been studied against other drugs in its class and has demonstrated high potency in reducing LDL-
Cholesterol levels and increasing HDL-Cholesterol. Pitavastatin has demonstrated a significant reduction in 
atherosclerotic plaque volumes and several pleiotropic effects, which suggest its potential benefits in reducing 
cardiovascular risk.  
At present, Pitavastatin don’t seem to have adverse effects on glucose metabolism; it has no adverse effects on renal 
function and currently there is no clinical evidence of Pitavastatin-induced hepatotoxicity. Pitavastatin has favorable 
pharmacokinetic and safety profiles and its characteristic structure provides significant efficacy at low doses.  
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INTRODUCTION 
Hyperlipidemia has a significant impact on public 
health, because this condition is a relevant risk factor 
for cardiovascular disease [1].  
Several guidelines recommend that Low Density 
Lipoprotein-Cholesterol (LDL-C) plasma level is the 
primary target of lipid lowering therapy, because it is 
most often associated with the risk for developing 
cardiovascular disease. Other secondary targets of 
therapy include reduction of serum triglycerides (TGs) 
and increase of High Density Lipoprotein-Cholesterol 
(HDL-C).  
Statins are frequently prescribed for the treatment of 
hyperlipidemia, especially for their ability to lower LDL-
C plasma levels [2-4].  
Statins act by inhibiting 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase, the rate-
determining enzyme in hepatic cholesterol synthesis; 
consequently, LDL-C receptors in the liver are raised 
thereby increasing the removal of LDL-C from the 
blood. 
Statins have also proved highly effective in reducing 
the risk of cardiovascular events in both primary and  
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secondary prevention studies. These results are also 
due to proven pleiotropic effects of this class of drugs, 
such as anti-inflammatory effects, antioxidant effects, 
anti-proliferative and immunomodulatory effects, 
plaque stability, normalization of sympathetic outflow, 
and prevention of platelet aggregation [5-7].  
Long since, different statins are available for the 
treatment of dyslipidemia: Atorvastatin, Simvastatin, 
Rosuvastatin, Lovastatin, Pravastatin, and Fluvastatin 
[5]. The newest entry in this class of drugs is 
Pitavastatin; it was first introduced in Japan in 2003 [8] 
and subsequently approved in many other countries, 
including United States of America, by the Food and 
Drug Administration in August 2009, and United 
Kingdom, by the Medicines and Healthcare products 
Regulatory Agency in August 2010. Pitavastatin has 
also been authorized in Italy in July 2012. However, 
Pitavastatin has not yet been worldwide introduced on 
a large scale. 
The purpose of the present study was to examine 
the latest evidences on Pitavastatin, more than 10 
years after its first marketing. 
MATERIAL AND METHODS 
A review of literature has been carried out via Pub 
Med, using the search term Pitavastatin. Search was 
not limited by language or human subjects. All the 
found items, published in the last 3 years (from January 
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2013 to January 2016), were analysed. Additional 
articles were selected from the bibliographies of the 
quoted references. 
RESULTS 
193 items were obtained: 40 clinical trials (34 
randomized controlled clinical trials), 26 multicenter 
studies, 25 comparative studies, 2 observational 
studies, 25 reviews (9 systematic review), 2 meta-
analysis, 2 case reports, 2 editorials, 2 comments, 5 
letters; the remaining items were prevalently other 
journal articles, research supports or other publication 
types. No guidelines or consensus were found. Most of 
the data were deduced from retrospective analysis and 
by careful assessment of the obtained items.  
The analysis of data obtained showed that 
Pitavastatin, the newest HMG-CoA reductase inhibitor 
approved for treating dyslipidemia, has demonstrated 
high efficacy in lowering serum concentrations of LDL-
C. The dose range for Pitavastatin is 1 to 4 mg orally 
once daily; results from a dose-finding trial indicate that 
the 1-mg dose decreases LDL-C concentrations by 
33.6% and the 4-mg dose decreases LDL-C levels by 
47.2% [9].  
Like other statins, Pitavastatin has also been shown 
to have various pleiotropic effects that help to prevent 
cardiovascular risk. Moreover, Pitavastatin has a 
unique metabolic profile that may offer therapeutic 
advantages and benefits. Pitavastatin also shows 
favorable and promising safety profile [10, 11]  
DISCUSSION AND CONCLUSION 
This review focuses on the most recent evidence 
regarding Pitavastatin and its differences compared to 
other available statins. 
Physicochemical Properties.  
Pitavastatin is a fully synthetic lipophilic statin which 
belongs to the class of organic compounds known as 
phenylquinolines; these are heterocyclic compounds 
containing a quinoline moiety substituted with a phenyl 
group. Pitavastatin is a lipid-lowering agent that 
competitively inhibits HMG-CoA reductase, the enzyme 
that catalyses the first step of cholesterol synthesis in 
the liver. Unlike other statins, Pitavastatin has a unique 
cyclopropyl group in its base structure and this 
chemical group contributes to a more effective 
inhibition of the HMG-CoA reductase enzyme in 
decreasing cholesterol production [9, 12]. 
Pharmacodynamics and Pharmacokinetics 
Pitavastatin, usually as a calcium salt, is available in 
strengths of 1 mg, 2 mg, and 4 mg; this drug is 51-60% 
bioavailable and achieves its peak plasma 
concentration (Cmax) approximately one hour after oral 
administration; plasma levels increase proportionally to 
the dose. Pitavastatin is more than 99% protein-bound 
in human plasma, mainly to albumin and alpha1-acid 
glycoprotein, and it is selectively distributed to the liver; 
after oral administration, most of the bioavailable 
Pitavastatin is excreted unchanged in the bile and it is 
reabsorbed by the intestine and recirculates to the liver 
making itself available for enterohepatic recirculation.  
Pitavastatin is mainly metabolized in the liver by 
glucuronidation; the cytochrome P450 system is only 
slightly involved in the metabolism of Pitavastatin; there 
is some metabolism by CYP2C9 and, to a lesser 
extent, CYP2C8, whereas Pitavastatin don't appears to 
be a substrate of cytochrome P3A4. As opposed to 
other statins, it's likely that the cyclopropyl group of 
Pitavastatin diverts the drug away from metabolism by 
cytochrome P450 system. As a result, Pitavastatin is 
minimally metabolized and these processes probably 
increase the bioavailability of Pitavastatin contributing 
to its prolonged duration of action; the mean plasma 
concentration half-life is 12 hours. Most of Pitavastatin 
is eventually excreted in the feces and approximately 
15% of dose in the urine.  
Taking Pitavastatin with fat meals decreases Cmax 
by 43%, whereas the area-under-the curve (AUC) 
concentration remains relatively unchanged. Cmax and 
AUC concentration don't differ when Pitavastatin is 
taken in the morning or evening. Moreover, the 
pharmacokinetic of Pitavastatin has been explored in a 
variety of patient groups with overlapping results, 
suggesting that dosage adjustments of this statin are 
not required for gender, age or race. 
According to the results of several pharmacokinetic 
studies, Pitavastatin shows favorable and promising 
safety profile; moreover its unique metabolism reduces 
the likelihood of clinically significant drug-drug 
interactions. [9, 13-17]. 
Hypolipidemic Effect 
Pitavastatin has been studied against other drugs in 
its class and has demonstrated high potency in 
reducing both total and LDL cholesterol levels; it was 
observed that Pitavastatin also significantly decreases 
the serum levels of TGs [9]. 
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Mean percentage of LDL-C and total cholesterol 
(TC) reductions from baseline were significantly greater 
with Pitavastatin 2 mg daily compared to Pravastatin 10 
mg daily [18].  
Pitavastatin 2 mg once daily was also compared 
with Simvastatin 20 mg dilay. Pitavastatin was non-
inferior to Simvastatin in terms of reducing LDL-C 
levels; there was no significant difference between two 
groups in changes in TC, TGs, or HDL-C levels [19].  
Several comparative studies showed that 
Pitavastatin and Atorvastatin didn't differ significantly in 
terms of reductions in LDL-C, TC, and TGs or 
increases in HDL-C [20,21]. A recent meta-analysis of 
seven trials involving 1.529 patients, revealed that 
Pitavastatin was as effective as Atorvastatin in lowering 
LDL-C, TC and TGs levels; moreover Pitavastatin was 
significantly superior to Atorvastatin in increasing HDL-
C levels [22].  
In the PATROL trial was compared the safety and 
efficacy of Pitavastatin 2 mg daily, Atorvastatin 10 mg 
daily and Rosuvastatin 2.5 mg daily, for 16 weeks, in 
302 patients with hypercholesterolemia; in this first 
prospective randomized multi-center trial Pitavastatin 
was non-inferior to the other two statins in lowering 
LDL-C levels [23].  
No comparative studies have been found between 
Pitavastatin and Lovastatin nor between Pitavastatin 
and Fluvastatin regarding their effectiveness in lipid-
lowering therapy. A comparison of the efficacy of 
available statins in lowering HDL-C is summarized in 
Table 1. 
Effect on Atherosclerosis 
Several studies have demonstrated that Pitavastatin 
has stronger effects on the regression and stabilization 
of atherosclerotic plaque in the thoracic aorta, carotid 
and coronary arteries [27-29]. In many studies the 
administration of Pitavastatin resulted in a significant 
regression of the carotid intima-media thickness [30, 
31]; moreover Pitavastatin not only improved the 
atherosis as measured by intima-media thickness and 
integrated backscatter values, but also attenuated 
inflammation of plaques as measured by maximum 
standard uptake values by PET/CT in the thoracic aorta 
and carotid artery [27]. These antiatherogenic effects of 
Pitavastatin were non-inferior to other statins 
administered in comparative studies, as Pravastatin 
[27, 28, 30] and Atorvastatin [29].  
Ancillary Benefits 
As other statins [32, 33], several experimental and 
clinical evidence suggest that Pitavastatin also has 
beneficial pleiotropic effects beyond its cholesterol-
lowering properties. These cholesterol-independent 
effects play an important part in reducing 
cardiovascular mortality and morbidity [34] and they 
include improving endothelial function and reducing 
oxidative stress [35-41], attenuating vascular and 
myocardial remodeling [42, 43], decreasing in smooth 
muscle proliferation [44, 45], inhibiting vascular 
inflammation [46-48], antiplatelet [49, 50] and 
antithrombotic actions [51]. 
As Atorvastatin [52], Pitavastatin improves 
endothelial function even in chronic smokers through 
its anti-oxidative properties. Pitavastatin has been 
shown to restore significantly the endothelial function in 
chronic smokers with mild hypercholesterolemia, after 
treatment for 4 weeks, suggesting a possible role in 
reducing cardiovascular events not only by lowering 
LDL-C levels but also by improving endothelial function 
[53]. 
Table 1: Comparison of the Efficacy in Lowering HDL-C between Available Statins [24-26, 9, 14] 
Statin 1 mg 2 mg 4 mg 5 mg 10 mg 20 mg 40 mg 80 mg 
Simvastatin n.a.(*) n.a.(*) n.a.(*) n.a.(*) -27%  -32%  -37%  -42% 
Lovastatin n.a.(*) n.a.(*) n.a.(*) n.a.(*) -21% -29% -37% -45% 
Fluvastatin n.a.(*) n.a.(*) n.a.(*) n.a.(*) n.a.(*) -21% -27% -36% 
Pravastatin n.a.(*) n.a.(*) n.a.(*) n.a.(*) -20% -24%  -29%  n.a.(*) 
Atorvastatin n.a.(*) n.a.(*) n.a.(*) n.a.(*) -37% -43% -49% -55% 
Rosuvastatin n.a.(*) n.a.(*) n.a.(*) -38%  -43%  -48%  -53%  n.a.(*) 
Pivastatin -33% -37% -47% n.a.(*) n.a.(*) n.a.(*) n.a.(*) n.a.(*) 
HDL-C reduction (%) 
(*) n.a. = not available 
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Effect in Reducing Cardiovascular Risk 
There is a lot of evidence that the statin therapy 
reduces the cardiovascular risk and several studies 
have demonstrated the efficacy of treatment with HMG-
CoA reductase inhibitors in primary [54-58] and 
secondary prevention [58-60]. The efficacy in reducing 
cardiovascular diseases has been shown with many 
statins [54-60] but, regarding the efficacy of 
Pitavastatin in preventing cardiovascular diseases, in 
our research we have not found significant studies 
having a cardiovascular event as either a primary or 
secondary end-point. We have found only a 
comparative study designed to evaluate the preventive 
effect of Pitavastatin and other statins on 
cardiovascular events in Japanese patients who 
underwent percutaneous coronary intervention [61]. 
This is a retrospective, single-center observational 
study carried out, for seven years, on 743 patients 
receiving Pitavastatin, Atorvastatin, Pravastatin, or no 
statin. This study has shown that each statin treatment 
significantly decreased recurrent cardiac events 
compared with no statin and Pitavastatin resulted more 
effective than other statin treatments. The main 
limitation of this study is that cardiac events 
predominantly consisted of repeted percutaneous 
coronary intervention, a relatively "soft" end-point. The 
main mechanisms by which Pitavastatin might reduce 
cardiovascular risk are summarized in Table 2. There is 
no doubt that the efficacy of Pitavastatin in reducing 
HDL-C and improving lipid profile, added to pleiotropic 
effects of this statin and its strong effects on the 
regression and stabilization of atherosclerotic plaque, 
may represent sufficient data to state that Pitavastatin 
is also effective in reducing cardiovascular risk. 
However, we believe that further studies will be needed 
to irrefutably confirm the efficacy of Pitavastatin in the 
prevention of cardiovascular risk.  
Safety and Drug Interactions 
Pitavastatin has pharmacodynamic and 
pharmacokinetic properties that are distinct from those 
of other statins, and may contribute to its favorable 
profile of safety [9-17].  
The safety of Pitavastatin was assessed in the 
LIVES Study, a Japanese long-term prospective post-
marketing surveillance study, designed to follow 
approximately 20.000 hypercholesterolemic patients 
treated with Pitavastatin [62]. 
During a 2-year follow-up period, no significant 
problems concerning safety were observed [63]; after 
104 weeks, only 10.4% of pitavastatin-treated patients 
experienced adverse events, of which approximately 
84% were mild and around 1% was severe. The most 
common adverse effects were myalgia (1.1%) and 
increases in blood creatine phosphokinase (2.7%), 
alanine aminotransferase (1.8%), aspartate 
aminotransferase (1.5%) and gamma-
glutamyltransferase (1.0%); only 7.4% of patients were 
forced to discontinue Pitavastatin [64]. This study 
revealed no unexpected negative side effects of 
Pitavastatin treatment, confirming the general long-
term safety and tolerability of this statin, as observed 
for Atorvastatin, Simvastatin and Rosuvastatin 
administered for extended periods in previous studies 
[65, 66]. Moreover, comparisons between Pitavastatin 
and other statins, as Atorvastatin, Rosuvastatin and 
Simvastatin, have shown that these statins have similar 
adverse event profiles [23, 67].  
Recent evidence have suggested that statin therapy 
could be associated with an increased risk of 
developing type 2 diabetes mellitus [68-70]. A meta-
analysis of 13 clinical trials (n = 91.140 patients without 
type 2 diabetes mellitus) indicates that standard doses 
of Atorvastatin, Pravastatin, Simvastatin, or 
Rosuvastatin were associated with a 9% increased risk 
for type 2 diabetes mellitus over 4 years. However this 
meta-analysis included trials with more than 1.000 
patients, with identical follow-up in both groups and 
duration of more than 1 year [70]. 
More recently, a meta-analysis of 17 randomized 
controlled trials, including 113.394 patients without 
preexisting type 2 diabetes mellitus, showed that, when 
compared with placebo, Pravastatin 40 mg daily was 
Table 2: Potential Mechanisms of Pitavastatin in 
Cardiovascular Risk Prevention [9, 27-31, 34-
53] 
• LDL- and Total-Cholesterol reduction 
• HDL-Cholesterol increase 
• Triglycerides reduction 
• Regression and stabilization of atherosclerotic plaque 
• Regression of carotid intima-media thickness 
• Improvement of endothelial function  
• Oxidative stress reduction  
• Attenuation of vascular and myocardial remodeling  
• Reduction of smooth muscle cells proliferation  
• Inhibition of vascular inflammation  
• Antiplatelet and antithrombotic actions 
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associated with the lowest risk for new-onset diabetes 
while Rosuvastatin 20 mg daily was associated with 
25% increased risk for diabetes; the impact on diabetes 
appeared to be intermediate with Atorvastatin 80 mg 
daily [71]. These findings confirm that different types 
and doses of statins show different potential to 
increase the incidence of new-onset diabetes.  
The efficacy and safety of Pitavastatin have also 
been assessed in patients with hyperlipidemia and 
concomitant glucose intolerance [72] or type 2 diabetes 
[73]; in these studies Pitavastatin has not caused 
adverse effect on glycemic control. Subsequently, a 
sub-analysis of LIVES Study [64] has shown an 
improvement in glycated hemoglobin in patients with 
type 2 diabetes after long-term Pitavastatin treatment. 
Recently, neutral effects of Pitavastatin on glucose 
homeostasis were observed in two cohorts of patients 
with metabolic syndrome; however small number of 
patients and short follow-up represent limitations of this 
study [74].  
In a more recent meta-analysis including 15 studies, 
Pitavastatin did not adversely affect glucose 
metabolism or diabetes development compared with 
placebo or other statins [75]. At present, Pitavastatin 
does not seem to have effects on the incidence of 
diabetes; the considerable increase in plasma 
adiponectin, documented in clinical studies, might be 
related to its favorable effect on glucose metabolism 
[76]. However, more studies are needed in well-
controlled trials. 
In the LIVES Study the treatment with Pitavastatin 
has allowed to obtain a significant increase in 
estimated glomerular filtration rate in patients with 
chronic kidney disease [77]. In a recent randomized 
trial [78] the renal effects of Pitavastatin, compared with 
Rosuvastatin, were assessed in dyslipidemic patients 
with chronic renal disease. The results of this study 
suggest that neither of these statins has adverse 
effects on renal function; however, in intra-group 
comparisons, the glomerular filtration rate was 
significantly increased in the Rosuvastatin group but 
not in the Pitavastatin group and showed no tendency 
to worsen in either groups.  
Finally, in a recent observational study [79], 
Pitavastatin resulted to be inferior to Pravastatin, 
Rosuvastatin and Atorvastatin in preserving the kidney 
function in patients with type 2 diabetes.  
It is reasonable that patients with moderate renal 
impairment and those receiving hemodialysis should 
begin with a starting dose of 1 mg and a maximum 
dose of 2 mg once daily. Patients with severe renal 
impairment who are not receiving hemodialysis have 
not been studied, and the use of Pitavastatin in this 
population is not recommended. 
In contrast to other lipophilic statins, Pitavastatin 
undergoes limited metabolism by cytochrome P450 
enzymes, particularly CYP3A4 which is a common 
source of drug interactions in other statins [80]. Clinical 
evidence suggests that concomitant therapy with drugs 
that are involved with the cytochrome P450 system has 
no effect on the pharmacokinetics of Pitavastatin [81, 
82]. 
Although in literature [83, 84] are reported cases of 
hepatotoxicity due to statins, in our research we have 
not found clinical evidence of Pitavastatin-induced 
hepatotoxicity; however, patients with acute liver 
disease, including unexplained and persistent 
increases in transaminases, should not receive 
Pitavastatin [85]. 
In conclusion, the newest HMG-CoA reductase 
inhibitor Pitavastatin has been studied against other 
drugs in its class and has demonstrated high potency 
in reducing both total and LDL cholesterol levels; 
moreover, Pitavastatin has been shown to be effective 
in increasing HDL-C and reducing TGs. Pitavastatin 
treatment has demonstrated a significant reduction in 
atherosclerotic plaque volumes and several pleiotropic 
effects, which suggest its potential benefits in reducing 
cardiovascular risk. In particular, Pitavastatin improves 
endothelial function and reduces oxidative stress; this 
effect has also been demonstrated in chronic smokers. 
At present, Pitavastatin don’t seem to have adverse 
effects on glucose metabolism; moreover this statin 
has no adverse effects on renal function and currently 
there is no clinical evidence of Pitavastatin-induced 
hepatotoxicity. 
Pitavastatin has favorable pharmacokinetic and 
safety profiles and its characteristic structure provides 
significant efficacy at low doses compared to other 
statins.  
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